Atlanta Psychiatrist Invested in Healthcare AI Startup

Dr. Munjal Shroff backed Healz AI after the tool helped identify his wife's rare cancer diagnosis.

Updated on Sept. 26, 2026 in Cancer

Isometric editorial illustration featuring a precision lens over interconnected glass data cubes, representing advanced diagnostic medical technology. — Atlanta psychiatrist Dr. Munjal Shroff has invested in Healz AI, a medical diagnostic platform that helped identify his wife's rare medical condition. AI Illustration. Upload story photo >

Live Poll

Would you trust an AI chatbot to help navigate your personal healthcare or treatment decisions?

Atlanta psychiatrist Dr. Munjal Shroff has invested in Healz AI, a medical startup whose diagnostic tool helped secure a rare T-cell lymphoma diagnosis for his wife. The AI assistant recommended an evaluation at the University of Texas MD Anderson Cancer Center after analyzing her symptoms.

Why it matters

The investment underscores the growing role of artificial intelligence in navigating complex medical cases. Shroff opted to fund the company specifically because he believes the technology prevented critical delays in his wife's treatment process.

Healz AI serves a user base consisting of 97% cancer patients and maintains a 70% month-to-month user retention rate. The system processes large volumes of medical documents and asks up to 20 follow-up questions before providing guidance.

The players

Munjal Shroff

Dr. Munjal Shroff is a psychiatrist based in Atlanta who recently invested in the healthcare technology firm Healz AI.

Healz AI

Healz AI is a healthcare technology startup that utilizes an AI assistant tool to help patients store and analyze large volumes of medical documents.

University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center is a global institution in Houston that provides comprehensive patient care, research, and education for cancer.

Recursive Superintelligence

Recursive Superintelligence is the parent company behind Healz AI that recently raised $650 million at a $4.65 billion valuation.

The details

The platform utilizes a specialized memory system designed to digest and store large amounts of medical documentation for complex analysis. By systematically querying symptoms through targeted follow-up questions, the tool aims to assist users in identifying rare medical conditions.

Fall 2025: Dr. Shroff's wife began experiencing unexplained health symptoms.
2025: Healz AI launched its beta version.
June to August 2026: The startup's recurring revenue doubled each month.
Early September 2026: Annual recurring revenue reached $100,000.

The Big Picture

The integration of AI diagnostics into clinical pathways reflects a broader trend of leveraging digital assistants to bridge the gap between patient symptoms and elite care facilities like the University of Texas MD Anderson Cancer Center.

Patients may find that AI diagnostic tools offer a way to organize complex medical records and potentially accelerate the path to specialist evaluations. However, users should remain aware that these tools are intended to assist in symptom analysis rather than replace formal clinical diagnoses.

The takeaway

Artificial intelligence is increasingly serving as a personal digital assistant for patients navigating the complexities of chronic or rare disease management. While these tools can help streamline information, they serve best as a supplement to expert guidance from specialized medical centers.